DOCSLIB.ORG

Appendix F6. Medstar Family Choice (Medstar) Prescription Drugs Subject to Nqtls, by Delivery System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix F6. Medstar Family Choice (Medstar) Prescription Drugs Subject to Nqtls, by Delivery System Appendix F6. MedStar Family Choice (MedStar) Prescription Drugs Subject to NQTLs, by Delivery System Prescription Drug Formulary Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Eucrisa 2 % topical ointment N Y ciclopirox 0.77 % topical cream N Y ciclopirox 0.77 % topical suspension N Y Sklice 0.5 % lotion N Y Bethkis 300 mg/4 mL solution for nebulization Y N Gralise 300 mg tablet,extended release Y N Gralise 30-Day Starter Pack 300 mg (9)-600 mg (69) tablet, Y N ext. release Gralise 600 mg tablet,extended release Y N Esbriet 267 mg capsule Y N Esbriet 267 mg tablet Y N Esbriet 801 mg tablet Y N Ofev 100 mg capsule Y N Ofev 150 mg capsule Y N Nucala 100 mg subcutaneous solution Y N Juxtapid 10 mg capsule Y N Juxtapid 20 mg capsule Y N Juxtapid 5 mg capsule Y N Lovaza 1 gram capsule Y N Aimovig Autoinjector 140 mg/mL subcutaneous auto- Y N injector Aimovig Autoinjector 70 mg/mL subcutaneous auto-injector Y N Alecensa 150 mg capsule Y N Alunbrig 30 mg tablet Y N Balversa 3 mg tablet Y N Balversa 4 mg tablet Y N Balversa 5 mg tablet Y N Bosulif 100 mg tablet Y N Bosulif 400 mg tablet Y N Bosulif 500 mg tablet Y N Braftovi 50 mg capsule Y N Cabometyx 20 mg tablet Y N Appendix F6 1 Appendix F6. MedStar Family Choice (MedStar) Prescription Drugs Subject to NQTLs, by Delivery System Prescription Drug Formulary Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Cabometyx 40 mg tablet Y N Cabometyx 60 mg tablet Y N Cometriq 100 mg/day (80 mg x 1-20 mg x 1) capsules Y N Cometriq 140 mg/day (80 mg x 1-20 mg x 3) capsules Y N Cometriq 60 mg/day (20 mg x 3/day) capsules Y N Cotellic 20 mg tablet Y N Eligard 22.5 mg (3 month) subcutaneous syringe Y N Eligard 30 mg (4 month) subcutaneous syringe Y N Eligard 45 mg (6 month) subcutaneous syringe Y N Eligard 7.5 mg (1 month) subcutaneous syringe Y N Erwinaze 10,000 unit solution for injection Y N Hycamtin 0.25 mg capsule Y N Hycamtin 1 mg capsule Y N Ibrance 100 mg capsule Y N Ibrance 125 mg capsule Y N Ibrance 75 mg capsule Y N Iclusig 15 mg tablet Y N Iclusig 45 mg tablet Y N Imbruvica 140 mg capsule Y N Imbruvica 140 mg tablet Y N Imbruvica 280 mg tablet Y N Imbruvica 420 mg tablet Y N Imbruvica 560 mg tablet Y N Imbruvica 70 mg capsule Y N Jakafi 10 mg tablet Y N Jakafi 15 mg tablet Y N Jakafi 20 mg tablet Y N Jakafi 25 mg tablet Y N Jakafi 5 mg tablet Y N Kymriah 0.6 x 10exp8 to 6 x10exp8 cell intravenous Y N suspension leuprolide 1 mg/0.2 mL subcutaneous kit Y N Appendix F6 2 Appendix F6. MedStar Family Choice (MedStar) Prescription Drugs Subject to NQTLs, by Delivery System Prescription Drug Formulary Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Libtayo 50 mg/mL intravenous solution Y N Lorbrena 25 mg tablet Y N Lumoxiti 1 mg intravenous solution Y N Lupron Depot (6 Month) 45 mg intramuscular syringe kit Y N Lupron Depot 11.25 mg (3 month) intramuscular syringe kit Y N Lupron Depot 22.5 mg (3 month) intramuscular syringe kit Y N Lupron Depot 3.75 mg intramuscular syringe kit Y N Lupron Depot 30 mg (4 month) intramuscular syringe kit Y N Lupron Depot 7.5 mg intramuscular syringe kit Y N Lupron Depot-Ped 11.25 mg (3 month) intramuscular Y N syringe kit Lupron Depot-Ped 11.25 mg intramuscular kit Y N Lupron Depot-Ped 15 mg intramuscular kit Y N Lupron Depot-Ped 7.5 mg (Ped) intramuscular kit Y N Mekinist 0.5 mg tablet Y N Mekinist 2 mg tablet Y N Mektovi 15 mg tablet Y N Nubeqa 300 mg tablet Y N Piqray 200 mg/day (200 mg x 1) tablet Y N Polivy 140 mg intravenous solution Y N Rozlytrek 100 mg capsule Y N Stivarga 40 mg tablet Y N Synribo 3.5 mg subcutaneous solution Y N Tafinlar 50 mg capsule Y N Tafinlar 75 mg capsule Y N Tagrisso 40 mg tablet Y N Tagrisso 80 mg tablet Y N Talzenna 0.25 mg capsule Y N Tarceva 100 mg tablet Y N Tarceva 150 mg tablet Y N Tarceva 25 mg tablet Y N Tasigna 150 mg capsule Y N Appendix F6 3 Appendix F6. MedStar Family Choice (MedStar) Prescription Drugs Subject to NQTLs, by Delivery System Prescription Drug Formulary Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Tasigna 200 mg capsule Y N Tasigna 50 mg capsule Y N Tibsovo 250 mg tablet Y N Turalio 200 mg capsule Y N Tykerb 250 mg tablet Y N Venclexta 10 mg tablet Y N Venclexta 100 mg tablet Y N Venclexta 50 mg tablet Y N Venclexta Starting Pack 10 mg-50 mg-100 mg tablets in a Y N dose pack Vizimpro 15 mg tablet Y N Vizimpro 30 mg tablet Y N Vizimpro 45 mg tablet Y N Xalkori 200 mg capsule Y N Xalkori 250 mg capsule Y N Xospata 40 mg tablet Y N Xpovio 160 mg/week (20 mg x 8) tablet Y N Zelboraf 240 mg tablet Y N Zoladex 10.8 mg subcutaneous implant Y N Zoladex 3.6 mg subcutaneous implant Y N Zydelig 100 mg tablet Y N Zydelig 150 mg tablet Y N Zykadia 150 mg tablet Y N Cutaquig 16.5 % subcutaneous solution Y N pretomanid 200 mg tablet Y N Sirturo 100 mg tablet Y N Noxafil 100 mg tablet,delayed release Y N Noxafil 200 mg/5 mL (40 mg/mL) oral suspension Y N Synjardy 12.5 mg-1,000 mg tablet Y N Tavalisse 150 mg tablet Y N Prolia 60 mg/mL subcutaneous syringe Y N Xgeva 120 mg/1.7 mL (70 mg/mL) subcutaneous solution Y N Appendix F6 4 Appendix F6. MedStar Family Choice (MedStar) Prescription Drugs Subject to NQTLs, by Delivery System Prescription Drug Formulary Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Amitiza 24 mcg capsule Y N Amitiza 8 mcg capsule Y N Nourianz 20 mg tablet Y N Nourianz 40 mg tablet Y N Xyrem 500 mg/mL oral solution Y N Firazyr 30 mg/3 mL subcutaneous syringe Y N Kalbitor 10 mg/mL (1 mL) subcutaneous solution Y N Lo Loestrin Fe 1 mg-10 mcg (24)/10 mcg (2) tablet Y N Minastrin 24 Fe 1 mg-20 mcg (24)/75 mg (4) chewable Y N tablet Natazia 3 mg/2 mg-2 mg/2 mg-3 mg/1 mg tablet Y N Orkambi 100 mg-125 mg oral granules in packet Y N Orkambi 100 mg-125 mg tablet Y N Orkambi 150 mg-188 mg oral granules in packet Y N Orkambi 200 mg-125 mg tablet Y N Kalydeco 150 mg tablet Y N Kalydeco 50 mg oral granules in packet Y N Kalydeco 75 mg oral granules in packet Y N Pulmozyme 1 mg/mL solution for inhalation Y N Endari 5 gram oral powder packet Y N Linzess 145 mcg capsule Y N Linzess 290 mcg capsule Y N Linzess 72 mcg capsule Y N Movantik 12.5 mg tablet Y N Movantik 25 mg tablet Y N Mavyret 100 mg-40 mg tablet Y N deferasirox 125 mg dispersible tablet Y N Doptelet (30 tab pack) 20 mg tablet Y N desmopressin 10 mcg/spray (0.1 mL) nasal spray Y N Jivi 1,000 (+/-) unit intravenous solution Y N Stimate 150 mcg/spray (0.1 mL) nasal spray Y N Mayzent 0.25 mg tablet Y N Appendix F6 5 Appendix F6. MedStar Family Choice (MedStar) Prescription Drugs Subject to NQTLs, by Delivery System Prescription Drug Formulary Prior Authorization (PA) NQTL Fail First/Step Therapy (FF/ST) NQTL Mayzent 2 mg tablet Y N Mayzent Starter Pack 0.25 mg (12 tabs) tablets Y N Fasenra 30 mg/mL subcutaneous syringe Y N Nucala 100 mg/mL subcutaneous auto-injector Y N Nucala 100 mg/mL subcutaneous syringe Y N Synagis 100 mg/mL intramuscular solution Y N Duragesic 50 mcg/hr transdermal patch Y N fentanyl 100 mcg/hr transdermal patch Y N fentanyl 12 mcg/hr transdermal patch Y N fentanyl 25 mcg/hr transdermal patch Y N fentanyl 37.5 mcg/hour transdermal patch Y N fentanyl 50 mcg/hr transdermal patch Y N fentanyl 62.5 mcg/hour transdermal patch Y N fentanyl 75 mcg/hr transdermal patch Y N fentanyl 87.5 mcg/hour transdermal patch Y N methadone 10 mg tablet Y N methadone 10 mg/5 mL oral solution Y N methadone 5 mg tablet Y N morphine ER 100 mg capsule,extended release pellets Y N morphine ER 100 mg tablet,extended release Y N morphine ER 15 mg tablet,extended release Y N morphine ER 200 mg tablet,extended release Y N morphine ER 30 mg capsule,extended release pellets Y N morphine ER 30 mg tablet,extended release Y N morphine ER 60 mg capsule,extended release pellets Y N morphine ER 60 mg tablet,extended release Y N Dificid 200 mg tablet Y N Ampyra 10 mg tablet,extended release Y N Onpattro 2 mg/mL intravenous solution Y N Repatha Pushtronex 420 mg/3.5 mL subcutaneous Y N wearable injector Repatha SureClick 140 mg/mL subcutaneous pen injector Y N Appendix F6 6 Appendix F6.
Load more

Recommended publications
  • VOLUME 7 2 . No. 4 . AUGUST 2 0
    VOLUME 72 . No.4 . AUGUST 2020 © 2020 EDIZIONI MINERVA MEDICA Minerva Pediatrica 2020 August;72(4):288-311 Online version at http://www.minervamedica.it DOI: 10.23736/S0026-4946.20.05861-2 REVIEW MANAGEMENT OF THE MAIN ENDOCRINE AND DIABETIC DISORDERS IN CHILDREN Current treatment for polycystic ovary syndrome: focus on adolescence Maria E. STREET 1 *, Francesca CIRILLO 1, Cecilia CATELLANI 1, 2, Marco DAURIZ 3, 4, Pietro LAZZERONI 1, Chiara SARTORI 1, Paolo MOGHETTI 4 1Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; 3Section of Endocrinology and Diabetes, Department of Internal Medicine, Bolzano General Hospital, Bolzano, Italy; 4Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy *Corresponding author: Maria E. Street, Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy. E-mail: [email protected] ABSTRACT Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in women and it is associated with an in- creased rate of infertility. Its etiology remains largely unknown, although both genetic and environmental factors play a role. PCOS is characterized by insulin resistance, metabolic disorders and low-grade chronic inflammation. To date, the treatment of PCOS is mainly symptomatic and aimed at reducing clinical signs of hyperandrogenism (hirsutism and acne), at improving menstrual cyclicity and at favoring ovulation. Since PCOS pathophysiology is still largely unknown, the therapeutic interventions currently in place are rarely cause-specific.
    [Show full text]
  • Oral Dosage Forms That Should Not Be Crushed Formulary-Specific List for VCMC and SPH
    Oral Dosage Forms That Should Not be Crushed Formulary-Specific List for VCMC and SPH Generic Brand Dosage Form(s) Reasons/Comments amoxicillin-clavulanate Augmentin XR Tablet Slow-release (b,h) aspirin Aspirin EC Caplet; Tablet Slow-release; Enteric-coated aspirin and dipyridamole Aggrenox XR Capsule Slow-release atazanavir Reyataz Capsule Note: an oral powder is available, see prescribing information for administration instructions atomoxetine Strattera Capsule Note: capsule contents can cause ocular irritation - Do not open capsules as contents are an ocular irritant benzonatate Tessalon Perles Capsule Note: swallow whole; local anesthesia of the oral mucosa; choking could occur - Capsules are liquid-filled “perles” - Do not alter (break, cut, chew) integrity of dosage form; local mucosal irritant and anesthetic bisacodyl Dulcolax Capsule; Tablet Enteric-coated (c) bosentan Tracleer Tablet Note: women who are, or may become, pregnant, should not handle crushed or broken tablets brivaracetam Briviact Tablet Film-coated (b) budesonide Entocort EC Capsule Enteric-coated (a) - Capsules contain enteric-coated granules in extended-release matrix; can open capsules but do not crush contents - Products are formulated to release active drug at mid- to late small intestine buPROPion Wellbutrin XL Tablet Slow-release - Do not crush extended-release tablets - Immediate-release tablet products may be film-coated March 2019 carvedilol phosphate Coreg CR Capsule Slow-release (a) (Note: may add contents of capsule to chilled, not warm, applesauce
    [Show full text]
  • Download Book
    Methods in Molecular Biology 2000 Volkmar Weissig Tamer Elbayoumi Editors Pharmaceutical Nanotechnology Basic Protocols M ETHODS IN M OLECULAR B IOLOGY Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Pharmaceutical Nanotechnology Basic Protocols Edited by Volkmar Weissig and Tamer Elbayoumi Department of Pharmaceutical Sciences, College of Pharmacy, Midwestern University, Glendale, AZ, USA Nanomedicine Center of Excellence in Translational Cancer Research, Midwestern University, Glendale, AZ, USA Editors Volkmar Weissig Tamer Elbayoumi Department of Pharmaceutical Sciences Department of Pharmaceutical Sciences College of Pharmacy, Midwestern University College of Pharmacy, Midwestern University Glendale, AZ, USA Glendale, AZ, USA Nanomedicine Center of Excellence Nanomedicine Center of Excellence in Translational Cancer Research in Translational Cancer Research Midwestern University Midwestern University Glendale, AZ, USA Glendale, AZ, USA ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-9515-8 ISBN 978-1-4939-9516-5 (eBook) https://doi.org/10.1007/978-1-4939-9516-5 © Springer Science+Business Media, LLC, part of Springer Nature 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc.
    [Show full text]
  • An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia Without Diabetes Joseph C
    Case Reports An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia without Diabetes Joseph C. Ratliff1 , Laura B. Palmese 1, Erin L. Reutenauer 1, Cenk Tek 1 Abstract A possible mechanism of antipsychotic-induced weight gain is activation of hypothalamic monophosphate-dependent kinase (AMPK) mediated by histamine 1 receptors. Alpha-lipoic acid (ALA), a potent antioxidant, counteracts this ef- fect and may be helpful in reducing weight for patients taking antipsychotics. The objective of this open-label study was to assess the efficacy of ALA (1,200 mg) on twelve non-diabetic schizophrenia patients over ten weeks. Participants lost significant weight during the intervention (-2.2 kg±2.5 kg). ALA was well tolerated and was particularly effective for individuals taking strongly antihistaminic antipsychotics (-2.9 kg±2.6 kg vs. -0.5 kg±1.0 kg). Clinical Trial Registra- tion: NCT01355952. Key Words: Schizophrenia, Obesity, Schizoaffective Disorder, Alpha-Lipoic Acid Introduction dependent protein kinase (AMPK) in the hypothalamus Antipsychotic medications appear to induce weight (4). In the periphery, AMPK increases energy utilization; gain, which results in increased rates of obesity in schizo- AMPK activity in the hypothalamus increases appetite. phrenia (1). Schizophrenia patients have significantly short- Several highly orexigenic (stimulates appetite) antipsy- er life expectancy than the general population (2); most of chotics such as clozapine, olanzapine, and quetiapine are this excess mortality is attributed to diabetes and cardiovas- shown to activate AMPK in the hypothalamus in animal cular disease (3); weight gain is a significant contributor to studies whereas other antipsychotic medications do not (4).
    [Show full text]
  • SUMMARY of PRODUCT CHARACTERISTICS 2.1 General Description 2.2 Qualitative and Quantitative Composition
    THERADOL 50 mg Effervescent tablets 1 Summary of product characteristics SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT THERADOL 50 mg Effervescent tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1 General description Round, biplane white or off-white tablets with bevel-edges on both sides. 2.2 Qualitative and quantitative composition Tramadol hydrochloride 50 mg per effervescent tablet. This product also contains sodium 214 mg, lactose 75 mg and aspartame 10 mg per tablet. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Effervescent tablet. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Treatment of moderate to severe acute and chronic pain, such as pain due to surgery, trauma, malignancy. 4.2. Posology and method of administration Posology As with all analgesic drugs, the dose of THERADOL 50 mg Effervescent tablets should be adjusted according to the intensity of the pain and the sensitivity of the individual patient. The lowest effective dose for analgesia should generally be selected. Adults and children aged 12 years and over: The usual dose is 50 to 100 mg (1 to 2 effervescent tablets), 3 to 4 times a day. In children from 12 to 14 years, it is recommended to use the lowest dose. Geriatric patients THERADOL 50 mg Effervescent tablets 2 Summary of product characteristics A dose adjustment is not usually necessary in patients up to 75 years without clinically manifest hepatic or renal insufficiency. In elderly patients over 75 years elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0236506 A1 SCHWARTZ Et Al
    US 2011 0236506A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0236506 A1 SCHWARTZ et al. (43) Pub. Date: Sep. 29, 2011 (54) PHARMACEUTICAL ASSOCIATION Publication Classification CONTAINING LIPOCACID AND (51) Int. Cl. HYDROXYCTRIC ACIDAS ACTIVE A633/24 (2006.01) INGREDIENTS A63L/385 (2006.01) A63/685 (2006.01) (75) Inventors: Laurent SCHWARTZ, Paris (FR): A63/4985 (2006.01) Adeline GUAIS-VERGNE, A63L/7056 (2006.01) Draveil (FR) A6IP35/00 (2006.01) (73) Assignees: Laurent SCHWARTZ, Paris (FR): (52) U.S. Cl. ........... 424/649; 514/440; 514/77: 514/249; BIOREBUS, Paris (FR) 514/52 (21) Appl. No.: 13/099,897 (57) ABSTRACT Pharmaceutical combination containing lipoic acid and (22) Filed: May 3, 2011 hydroxycitric acid as active ingredients. The present inven tion relates to a novel pharmaceutical combination and to the Related U.S. Application Data use thereof for producing a medicament having an antitumor (63) Continuation of application No. PCT/FR2009/ activity. According to the invention, this combination com 052110, filed on Nov. 2, 2009. prises, as active ingredients: lipoic acid or one of the pharma ceutically acceptable salts thereof, and hydroxycitric acid or (30) Foreign Application Priority Data one of the pharmaceutically acceptable salts thereof. Said active ingredients being formulated together or separately for Nov. 3, 2008 (FR) ....................................... O8574.48 a conjugated, simultaneous or separate use. Patent Application Publication Sep. 29, 2011 Sheet 1 of 9 US 2011/023650.6 A1 lipoic acid alone -29 f2 f Niger of ces i{t} v s 6 g i w 4. 6 8 i 2 Concentrations tumoi.i.
    [Show full text]
  • Immediate Hypersensitivity Reactions Caused by Drug Excipients: a Literature Review Caballero ML, Quirce S
    REVIEWS Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review Caballero ML, Quirce S Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain J Investig Allergol Clin Immunol 2020; Vol. 30(2): 86-100 doi: 10.18176/jiaci.0476 Abstract The European Medicines Agency defines excipients as the constituents of a pharmaceutical form apart from the active substance. Immediate hypersensitivity reactions (IHRs) caused by excipients contained in the formulation of medications have been described. However, there are no data on the prevalence of IHRs due to drug excipients. Clinical manifestations of allergy to excipients can range from skin disorders to life-threatening systemic reactions. The aim of this study was to review the literature on allergy to pharmaceutical excipients and to record the IHRs described with various types of medications, specifically reactions due to the excipients contained in their formulations. The cases reported were sorted alphabetically by type of medication and excipient in order to obtain a list of the excipients most frequently involved for each type of medication. Key words: Allergy. Drug immediate hypersensitivity reaction. Excipient. Pharmaceutical excipients. Resumen La Agencia Europea de Medicamentos define los excipientes como los componentes de una forma farmacéutica diferenciados del principio activo. Se han descrito reacciones de hipersensibilidad inmediata causadas por los excipientes contenidos en la formulación de medicamentos. Sin embargo, no hay datos sobre la prevalencia de dichas reacciones. Las manifestaciones clínicas de la alergia a los excipientes pueden ir desde trastornos de la piel hasta reacciones sistémicas que ponen en peligro la vida. El objetivo de este estudio fue realizar una revisión de la literatura sobre la alergia a los excipientes farmacéuticos y recopilar las reacciones inmediatas descritas con diferentes tipos de medicamento, debido solo a excipientes contenidos en sus formulaciones.
    [Show full text]
  • Spanish 2018 Rx4 Traditional Drug List
    Cambios Anuales de Rx4 Traditional 2018 Fecha de entrada en vigor: 01/01/2018 Para visualizarlo en español, haga clic aquí. To view your full Drug List, click here. ¡Bienvenido a Humana! Los cambios al formulario adjunto, o Lista de medicamentos, entran en vigor el 1 de enero de 2018. Visite Humana.com e inicie sesión en MyHumana –su cuenta en línea segura y personal– a partir de la fecha de su renovación para ver los beneficios de medicamentos recetados específicos, incluidos los copagos o el costo compartido, las limitaciones y las exclusiones. También puede consultar su Certificado de cobertura/seguro o su Descripción resumida del plan/Póliza de seguro. Si tiene preguntas: • Posibles afiliados: llamar a Atención al Cliente al número que aparece en los materiales de inscripción • Afiliados actuales: llamar al número indicado al reverso de su tarjeta de identificación de Humana Cómo leer los cambios a su Lista de medicamentos anual Algunos medicamentos cubiertos pueden tener requisitos adicionales o límites en la cobertura. Hable con su médico o proveedor de atención médica si su medicamento tiene un requisito adicional. Estos requisitos y límites pueden incluir: Estatus de la cobertura (CVG, por sus siglas en inglés): Ciertos medicamentos que anteriormente no estaban cubiertos en virtud de los beneficios de su plan se agregarán a su Lista de medicamentos para 2018, mientras que otros medicamentos que quizás estaban cubiertos en el pasado, se eliminarán. Tenga en cuenta que si usted surte o repite la receta de cualquier medicamento no cubierto en virtud de los beneficios de su plan, quizás deba pagar el costo total de su medicamento recetado.
    [Show full text]
  • Philadelphia
    Saturday, April 18th, 2015 PCOS Awareness Symposium 2015 Philadelphia Polycystic Ovary Syndrome: Creating a Treatment Plan Katherine Sherif, MD Professor & Vice Chair, Department of Medicine Director, Jefferson Women’s Primary Care Thomas Jefferson University The Canary in the Coalmine . PCOS seems to accelerate the aging process . It is possible to reverse the aging process . Be scrupulous in your commitment to be healthy Multiple Systems . Reproductive . Endocrinologic . Cardiac . Renal (kidney) . Hepatic (liver) . Brain (mood) . Dermatologic Multiple Signs & Symptoms Irregular periods, Bleeding too much, Bleeding too little, Anxiety, Depression, Eating disorders, Weight gain, Acanthosis nigricans, Skin tags, Follicular keratitis, Hirsutism, Acne, Alopecia, Excess sweating, Seborrheic dermatitis, Hidradenitis supparativa, Fatty liver, High triglycerides, low HDL-cholesterol, Elevated glucose, Infertility, Breastfeeding problems, Poor sleep, Miscarriages, Fatigue, Endometrial cancer Multiple Pathways GnRH pulsatility Theca cell LH Progesterone 17 - OH P testosterone estrone androstenedione & TGranulosa A* Estradiol X Follicle Peripheral conversion A* = aromatase More Pathways! GnRH Insulin pulsatility Theca cell LH Progesterone 17 - OH P testosterone estrone androstenedione testosterone estradiol X ↓ SHBG Free T X Follicle Peripheral conversion The Magic Bullet The oral contraceptive pill . High doses of estrogen (ethinyl estradiol) . Increase SHBG and lower free testosterone* . Improve skin symptoms in most: . Alopecia .
    [Show full text]
  • Effervescent Proliposomes for Aerosol Delivery to Paranasal Sinuses
    EFFERVESCENT PROLIPOSOMES FOR AEROSOL DELIVERY TO PARANASAL SINUSES BY OSHADIE KORALE A thesis submitted in partial fulfilment for the requirements for the degree of PhD at the University of Central Lancashire June, 2016 Dedication I dedicate this achievement to my parents, fiancé, brother, my grandmother and friends; without their encouragement and love this would not have been possible. 1 University of Central Lancashire STUDENT DECLARATION FORM Concurrent registration for two or more academic awards I declare that while registered as a candidate for the research degree, I have not been a registered candidate or enrolled student for another award of the University or other academic or professional institution ____________________________________________________________________________ Material submitted for another award I declare that no material contained in the thesis has been used in any other submission for an academic award and is solely my own work ____________________________________________________________________________ Signature of Candidate Type of Award Doctor of Philosophy (PhD) School Pharmacy and Biomedical Science, University of Central Lancashire 2 Abstract This study aims to design and develop effervescent proliposomes that could disintegrate in water and liberate liposomes, and to investigate the potential suitability of liposomes generated for aerosolization to target paranasal sinuses. Novel effervescent proliposomes prepared with Soya phosphatidylcholine (SPC) and Dipalmitoylphosphatidylcholine (DPPC) successfully generated stable liposomes with an improved disintegration time of less than 5 min. Differences in lipid composition were found to influence liposome size and drug entrapment of the hydrophobic drug Beclometasone dipropionate (BDP). Mannitol-based formulations developed with DPPC:Chol (1:1) produced liposomes of 7.54±0.15 µm with a drug entrapment efficiency of 82.15±8.29%.
    [Show full text]
  • MERCHANT SHIPPING (SEAFARERS) (MEDICAL STORES) REGULATION (Cap
    MERCHANT SHIPPING (SEAFARERS) (MEDICAL STORES) REGULATION (Cap. 478 sections 96, 100 and 134) [2 September 1996] PART I PRELIMINARY 1. (Omitted as spent) 2. Interpretation (1) In this Regulation, unless the context otherwise requires— “chemical” ( 化 學 品 ) means any chemical listed in the following International Maritime Organization publications— (a) the General Index of the International Maritime Dangerous Goods Code; (b) the Index of Dangerous Chemicals Carried in Bulk; or (c) Chapter XIX of the International Code for the Construction and Equipment of Ships Carrying Liquefied Gases in Bulk; “crew” (船員) means all seafarers employed on board a ship; “employer” (僱主) means the person for the time being employing the master; “IMDG Code” (《國際海運危險貨物守則》) means the 1988 edition of the International Maritime Dangerous Goods Code published by the International Maritime Organization; “offshore installation” (離岸裝置) means any installation which is maintained, or is intended to be established, for underwater exploitation or exploration; “seagoing” (海域航行), in relation to a ship, means any ship other than a ship which navigates exclusively within inland waters or in areas where port regulations apply; “submersible craft” (潛水艇) means any vessel used or designed for use under the surface of any waters; “voyage” (航程) means a journey from a port to the next port of call of a ship (which may be the same port). (2) Any reference in this Regulation to the British Pharmacopoeia, the European Pharmacopoeia, or the British National Formulary shall in its application to a particular case be construed as a reference to the edition thereof current at, or not more than 3 months before, the time when any requirement of this Regulation has effect.
    [Show full text]
  • Mitochondrial Dysfunction and Chronic Inflammation in Polycystic
    International Journal of Molecular Sciences Review Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome Siarhei A. Dabravolski 1,*, Nikita G. Nikiforov 2,3,4, Ali H. Eid 5,6,7, Ludmila V. Nedosugova 8, Antonina V. Starodubova 9,10, Tatyana V. Popkova 11, Evgeny E. Bezsonov 4,12 and Alexander N. Orekhov 4 1 Department of Clinical Diagnostics, Vitebsk State Academy of Veterinary Medicine [UO VGAVM], 7/11 Dovatora Str., 210026 Vitebsk, Belarus 2 Center of Collective Usage, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilova Street, 119334 Moscow, Russia; [email protected] 3 Laboratory of Medical Genetics, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, 121552 Moscow, Russia 4 Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Institute of Human Morphology, 3 Tsyurupa Street, 117418 Moscow, Russia; [email protected] (E.E.B.); [email protected] (A.N.O.) 5 Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha 2713, Qatar; [email protected] 6 Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha 2713, Qatar 7 Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon 8 Citation: Dabravolski, S.A.; Federal State Autonomous Educational Institution of Higher Education, I. M. Sechenov First Moscow State Nikiforov, N.G.; Eid, A.H.; Medical University (Sechenov University), 8/2 Trubenskaya Street, 119991 Moscow, Russia; [email protected] 9 Federal Research Centre for Nutrition, Biotechnology and Food Safety, 2/14 Ustinsky Passage, Nedosugova, L.V.; Starodubova, A.V.; 109240 Moscow, Russia; [email protected] Popkova, T.V.; Bezsonov, E.E.; 10 Pirogov Russian National Research Medical University, 1 Ostrovitianov Street, 117997 Moscow, Russia Orekhov, A.N.
    [Show full text]